Physician Photo

Marc Dror (Dror) Michaelson, MD, PhD

Clinical Director, Genitourinary Cancer Center

  • Phone: 617-726-1594
Departments
Hematology/Oncology
Department of Medicine

Specialties

  • Cancer Center
  • Prostate Cancer
  • Testicular Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Genitourinary Oncology
Clinical Interests
Bladder cancer
Testicular, penile and genito-urinary cancers
Phase I Clinical Trials
Prostate cancer
Renal Cancer
Locations
Boston: Massachusetts General Hospital
Medical Education
MD, Ph.D., Albert Einstein College/Jacobi
Residency, Brigham and Women's Hospital
Fellowship, Brigham and Women's Hospital
Fellowship, Dana Farber Cancer Institute
Fellowship, Massachusetts General Hospital
Board Certifications
Medical Oncology, American Board of Internal Medicine
Gender
Male
Patient Age Group
Adult
Accepting New Patients
Yes

ResearchAt Mass General, we have participated in a number of crucial clinical trials that have shifted treatment in kidney cancer to targeted therapy with inhibition of angiogenesis. These trials have broadly impacted treatment of this disease and resulted in regulatory approval of new drugs including sunitinib. Dr. Michaelson has served on scientific advisory boards for a number of companies with an interest in developing targeted therapy for RCC, is a member of the NCCN Renal/Testicular Cancer Guidelines Panel, and also serves on the NCI RCC Task Force that is responsible for evaluating and modifying new clinical trial concepts. He currently leads and participates in phase 1 and phase 2 studies in RCC that hope to define tailored therapy for particular patient subpopulations in the move toward individualized cancer treatment. Regarding prostate cancer research, Dr. Michaelson has led an effort at Mass General and DFCI to characterize the activity of targeted therapy with sunitinib in men with advanced prostate cancer, and serves as the study chair for an international phase 3 trial in this patient population. Additionally, he has designed a phase 3 National Cancer Institute trial concept with a promising, novel hormonal agent in early high-risk prostate cancer. He also designed and leads a phase 1/2 NCI-sponsored cooperative group trial looking at combination of chemotherapy and targeted treatment together with radiation therapy in invasive bladder transitional cell carcinoma. Many of the efforts described above have been supported by peer-reviewed grants from the National Cancer Institute and Department of Defense, in addition to institutional sources.

Hematology/Oncology
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-726-1594
Phone 2: 617-724-4000
Fax: 617-726-3440